Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-15

Study Completion Date

2019-05-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neonatal sepsis has a high risk of morbidity and mortality. The current WHO and national guidelines recommend antibiotics to which resistance is reported in neonatal populations, although the available data is limited. Research on alternative empirical regimens for neonatal sepsis which are affordable, safe and cost-effective, with a step-down oral option, is needed. AMR is an issue of global public health concern and is one of the WHO's global health priority areas. Understanding the benefits, risks, MIC capacity and PK of fosfomycin will influence global policy on the case management of neonates with sepsis in Kenya and international settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates

NCT00850122

Sepsis Prematurity

COMPLETED PHASE1

Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China

NCT05089760

Antimicrobial Resistance Neonatal Sepsis

UNKNOWN

Population Pharmacokinetics of Amikacin in Neonates

NCT04867135

Neonatal Sepsis, Late-Onset

COMPLETED

Antibiotic Therapy for Early Onset Neonatal Sepsis

NCT03932123

Early Onset Neonatal Sepsis

RECRUITING

An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants

NCT00942149

Sepsis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antimicrobial resistance (AMR) has become a major issue in global health. Despite progress in the reduction of under 5 mortality rates in recent decades, the proportion of neonatal deaths occurring within this age group has increased, with almost one quarter of all neonatal deaths occurring due to serious bacterial infection. Common bacteria causing neonatal sepsis are now exhibiting widespread resistance to several classes of antibiotics. There is an urgent need to discover new, effective treatments and re-evaluate existing therapeutic agents to treat infections potentially caused by multi-drug resistant (MDR) pathogens. Gram-negative bacteria (GNB) predominate as the cause of neonatal sepsis, and are increasingly associated with high rates of resistance to the currently recommended WHO empirical therapy regimen of ampicillin/penicillin and gentamicin. There is therefore a need to develop an updated empiric regimen with improved efficacy in the context of increasing MDR sepsis in neonates. New antimicrobials under development will be expensive once licensed, and there are currently virtually no planned trials to assess their efficacy in neonates in low- and middle-income countries (LMICs).

One potential strategy is utilising an existing off-patent (and therefore affordable) antibiotic available in intravenous and oral formulations - fosfomycin. Fosfomycin has a wide spectrum of activity against Gram-positive and Gram-negative bacteria causing neonatal sepsis. It is mainly used for resistant urinary tract infections in adults, but has licenced neonatal and paediatric doses in Europe (though dosing regimens vary between countries). Both oral and IV formulations are available. A large clinical trial to assess the efficacy of a fosfomycin plus an aminoglycoside combination (compared to the current WHO recommended ampicillin and gentamicin) is anticipated, including sites in Kenya. The ultimate aim is for fosfomycin to be included in the WHO Essential Medicines List for children (EMLc) and be available for use in developing countries, where rates of resistance to ampicillin and gentamicin have been estimated at over 40%. The first steps before this trial are to clarify the pharmacokinetics (PK) and safety profile of fosfomycin in neonates, as well as generating further information regarding local patterns of bacterial susceptibility to fosfomycin. The aim of this study is to fulfil both these steps. Fosfomycin (IV and oral) PK will be investigated among 60 babies admitted to hospital and being treated for presumed sepsis; administered alongside the standard antibiotics. Another 60 babies receiving standard treatment only (without PK sampling) will be monitored in the same way to compare adverse events. In the laboratory at CGMR-C, previously archived bacterial isolates will be tested for their sensitivity to fosfomycin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neonatal SEPSIS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of Care

ampicillin 50mg/kg twice daily and gentamicin \[3mg/kg for babies \<2kg or 5mg/kg for babies \>2kg\] once daily for 7 days, as per Kenyan guidelines).

Group Type NO_INTERVENTION

No interventions assigned to this group

Standard of Care plus Fosfomycin

Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).

Group Type EXPERIMENTAL

Standard of Care + Fosfomycin

Intervention Type DRUG

Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).

PK

Intervention Type PROCEDURE

Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.

Analysis of Bacterial Isolates

Intervention Type PROCEDURE

For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard of Care + Fosfomycin

Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).

Intervention Type DRUG

PK

Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.

Intervention Type PROCEDURE

Analysis of Bacterial Isolates

For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

iv Fosfomycin oral Fosfomycin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 0 to 28 days inclusive
* Weight \>1500g
* Born (an estimated) \>34 weeks gestation (calculated as per the Ballard Maturational Assessment)
* Admitted to hospital and eligible to receive IV antibiotics, according to national guidelines

Exclusion Criteria

* Baseline sodium level \>= 150mmol/L
* Baseline creatinine \>= 150 micromol/L
* Presenting with severe (grade 3) Hypoxic Ischaemic Encephalopathy (HIE), defined as per Sarnat and Sarnat as a stuporous, flaccid infant (with or without seizure activity) with suppressed brainstem and autonomic functions and absent reflexes
* Requiring cardiopulmonary resuscitation on admission
* Jaundice requiring exchange transfusion
* Admitted as a transfer after an overnight inpatient stay at another hospital
* Known allergy or contraindication to fosfomycin
* A specific clinical indication for another class of antibiotic (other than the nationally recommended standard-of-care)
* More than 4 hours after initiating ampicillin plus gentamicin (one dose), which allows for administration of these first-line antibiotics not to be delayed by study procedures
* Concurrent participation in another clinical trial
* Attending clinician's judgement that the child is so severely ill that adequate communication about the study with the parent or legal guardian is not possible.
* Not planning to remain resident in the County for the next 28 days.
* Lack of consent

Maximum Eligible Age

28 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No